Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients.

This once-promising pot stock may not survive the year.

Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today

Insys Therapeutics Inc said on Friday that a cash crunch resulting from legal costs related to a U.S.

Insys says it may be forced to file for bankruptcy due to litigation cash crunch

Insys Therapeutics (INSY) delivered earnings and revenue surprises of -323.08% and -48.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates

A Boston jury convicted Insys Therapeutics founder John Kapoor and other former executives of racketeering and other crimes.

Insys Therapeutics founder, former executives found guilty in criminal fentanyl bribery case

Tilray Brands

Despite a blazing hot start to the year, these pot stocks look to be buzzkills.

3 Marijuana Stocks to Avoid Like the Plague in April

22nd Century Group

There are some very familiar marijuana stocks among this bunch of losers.

These Worst-Performing Pot Stocks Fell at Least 20% in March

Investors need to pay close attention to INSYS Therapeutics stock based on the movements in the options market lately.

Implied Volatility Surging for INSYS Therapeutics Stock Options

Insys Therapeutics (INSY) closed the most recent trading day at $4.62, moving +1.99% from the previous trading session.

Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know

Investors headed for the hills after the biotech's regulatory filing said that it could run out of cash in the not-too-distant future.

Why Insys Therapeutics Shares Crashed Today

Express

Roku

Find out what made these stocks miss another rally in the broader market.

Why Express, Roku, and Insys Therapeutics Slumped Today

Insys Therapeutics shares were crashing Wednesday.

Insys Therapeutics Shares Plunge After Auditor Raises Viability Concerns

Insys Therapeutics Inc., which specializes in painkillers and synthetic cannabinoid drugs, reported Thursday after the close with a sharp decline in revenue and a wider-than-expected loss in the fourth quarter.

Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts

Insys Therapeutics said it tapped Lazard to advise the drugmaker on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company's shares down 15 percent in after-hours trading.

News for Insys Therapeutics Stock (INSY)